AstraZeneca-Merck Lynparza gets EMA's positive recommendation
Drugmakers AstraZeneca Plc and Merck& Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Health | Merck | Pancreas | Pancreatic Cancer